- Home
- HLIO vs ZYME Comparison
HLIO vs ZYME Comparison
Compare HLIO & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HLIO | ZYME |
|---|---|---|
| Founded | 1970 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | HLIO | ZYME |
|---|---|---|
| Price | $57.33 | $26.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $52.40 | $29.50 |
| AVG Volume (30 Days) | 264.5K | ★ 1.7M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $807,700,000.00 | $134,481,000.00 |
| Revenue This Year | $4.43 | $64.45 |
| Revenue Next Year | $1.03 | $67.04 |
| P/E Ratio | $56.19 | ★ N/A |
| Revenue Growth | N/A | ★ 116.21 |
| 52 Week Low | $24.76 | $9.03 |
| 52 Week High | $58.80 | $28.49 |
Technical Indicators
Market Signals| Indicator | HLIO | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 62.20 | 62.08 |
| Support Level | $52.72 | $24.79 |
| Resistance Level | $57.91 | $26.46 |
| Average True Range (ATR) | 1.62 | 1.27 |
| MACD | 0.46 | -0.28 |
| Stochastic Oscillator | 90.34 | 35.60 |
Price Performance
Historical ComparisonAbout HLIO Helios Technologies Inc.
Helios Technologies Inc is a industrial technology company that develops, manufactures, and markets solutions for the hydraulics and electronics markets. It operates under two business segments: Hydraulics and Electronics. The Hydraulics segment designs and manufactures hydraulic cartridge valves, hydraulic quick release couplings as well as engineers complete hydraulic systems. The Electronics segment designs and manufactures customized electronic controls systems and displays for a variety of end markets including industrial and mobile, recreational and health and wellness. It derives maximum revenue from the Hydraulics Segment.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.